Outlook Therapeutics (OTLK) said Thursday it submitted a biologics license application to the Food and Drug Administration for its ONS-5010 investigational...
Kurt J Hilzinger, Director, on February 22, 2022, executed a purchase for 175,132 shares in Outlook Therapeutics (OTLK) for $256,970. Following the Form 4...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Ghiath M. Sukhtian, 10% Owner, Director, on November 29, 2021, executed a purchase for 16,000,000 shares in Outlook Therapeutics (OTLK) for $20,000,000....
| Address | 485 Route 1 South Iselin, New Jersey 08830 |
| Phone | +1.609.619.3990 |
| Number of Employees | 56 |
| Recent SEC Filing | 05/13/2022 10-Q |
| President, Chief Executive Officer & Director | C. Russell Trenary |
| Chief Operating Officer | Terry Dagnon |
| CFO, Secretary, Treasurer & Director | Lawrence A. Kenyon |
| Senior Vice President-Clinical Development | Jennifer M. Kissner |
| Price Open | $1.61 |
| Previous Close | $1.60 |
| 52 Week Range | $1.19 - 3.27 |
| Market Capitalization | $368.3 M |
| Shares Outstanding | 225.9 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/12/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.31 |
| Beta vs. S&P 500 | N/A |
| Revenue | $3.1 M |
| Net Profit Margin | N/A |
| Return on Equity | -244.94% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
